TCM
IMCR icon

Tybourne Capital Management’s Immunocore IMCR Stock Holding History

Tybourne Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-138,192
Closed -$5.4M – 26
2021
Q2 		$5.4M Hold
138,192
– – 0.11% 29
2021
Q1 		$5.88M Buy
+138,192
New +$6.15M 0.13% 32

Other funds holding IMCR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCPEMI
Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Tybourne Capital Management's IMCR Position: Q3 2021 in Review

Tybourne Capital Management sold out of Immunocore (IMCR) in Q3 2021, closing a stake of 138,192 shares — an estimated $5.4M sold.

Tybourne Capital Management first reported a position in IMCR in Q1 2021 and held it in 2 quarters. The position peaked at $5.88M in Q1 2021. 47 funds tracked by Wall St. Rank hold IMCR as of Q3 2021.

  • Tybourne Capital Management reported no remaining Immunocore position as of Q3 2021 after selling out during the quarter.
  • Tybourne Capital Management sold 138,192 Immunocore shares in Q3 2021, an estimated $5.4M.
  • Tybourne Capital Management first reported a position in Immunocore in Q1 2021 and held it in 2 quarters.
  • Tybourne Capital Management's Immunocore position peaked at $5.88M in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Immunocore as of Q3 2021.

Based on Tybourne Capital Management's 13F filing for Q3 2021, filed 27 Oct 2021.